MISSISSAUGA, ON, Oct. 24, 2011 /PRNewswire/ - Covalon Technologies Ltd. (the
"Company" or "Covalon") (TSXV: COV), an advanced medical technologies
company, today announced that Dr. Val DiTizio, Chief Scientific Officer
and co-founder of Covalon will be speaking at this year's BioInterface
2011 Workshop and Symposium held from October 24th to 26th in
Dr. Val DiTizio, Ph.D. will be presenting 'Bioactive Organic Coatings
for Orthopedic Devices' to a cross section of industry, academic,
regulatory and clinical professionals from a variety of disciplines on
Wednesday October 26, at 3:40 pm Central Time. Dr. DiTizio has over 20
years of experience creating bioactive surfaces and holds a masters and
a doctorate from the University of Toronto. Dr. DiTizio holds a number
of patents in the areas of surface modification, liposomal delivery
systems, collagen matrices and antimicrobial medical devices.
Dr. DiTizio states, "A new generation of materials and devices are
addressing the challenges of improving performance through deliberate
manipulation of biological activities. The addition of "smart coatings"
to orthopedic devices can lead to many useful and clinically relevant
The BioInterface conference is focused on providing a venue where the
most recent innovations and ideas can be presented and discussed. A
broad range of topics covered by the conference include biomaterials,
surface modification of devices, wound healing, drug delivery, and
regulatory issues. The conference has a strong applied focus and brings
together representatives from industry, academic, clinical and
"We are honored to have Dr. DiTizio present at this year's BioInterface
Symposium," said Brian Pedlar, Chief Executive Officer of Covalon. "Dr.
DiTizio is one of the world leaders in the field of combining medical
devices and bioactive organic coatings. His work over the past twelve
years as Chief Scientific Officer with Covalon has generated a deep
portfolio of proprietary intellectual property and medical device
achievements. The scientific team from Covalon's large and small
medical device customers have truly benefited from Val's knowledge and
experience as they tackle challenges associated with introducing
bioactive coated devices into the medical marketplace."
To learn more about Covalon's products and services, please contact
Brian Pedlar, CEO Covalon Technologies Ltd. at firstname.lastname@example.org
Covalon Technologies Ltd. researches, develops and commercializes new
healthcare technologies that help save lives around the world.
Covalon's patented technologies, products and services address the
advanced healthcare needs of medical device companies, healthcare
providers and individual consumers. Covalon's technologies are used to
prevent, detect and manage medical conditions in specialty areas such
as wound care, tissue repair, infection control, disease management,
medical device coatings and biocompatibility. To learn more about
Covalon, visit our website at www.covalon.com
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking statements which reflect the
Company's current expectations regarding future events. The
forward-looking statements are often, but not always, identified by the
use of words such as "seek", "anticipate", "plan, "estimate", "expect",
"intend" and statements that an event or result "may", "will",
"should", "could" or "might" occur or be achieved and other similar
expressions. These forward-looking statements involve risk and
uncertainties, including the difficulty in predicting product
approvals, acceptance of and demands for new products, the impact of
the products and pricing strategies of competitors, delays in
developing and launching new products, the regulatory environment,
fluctuations in operating results and other risks, any of which could
cause results, performance, or achievements to differ materially from
the results discussed or implied in the forward-looking statements.
Many risks are inherent in the industry; others are more specific to
the Company. Investors should consult the Company's ongoing quarterly
filings for additional information on risks and uncertainties relating
to these forward-looking statements. Investors should not place undue
reliance on any forward-looking statements. The Company assumes no
obligation to update or alter any forward-looking statements whether as
a result of new information, further events or otherwise.
SOURCE Covalon Technologies Ltd.